An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang